Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-throughput approaches to discover novel immunomodulatory agents for cancer.

Literature DB >> 23243609

High-throughput approaches to discover novel immunomodulatory agents for cancer.

Douglas W McMillin¹, Constantine S Mitsiades.

Abstract

The clinical success of immunomodulatory thalidomide derivatives has renewed the general interest in immunomodulatory anticancer compounds and prompted us to develop a high-throughput system to quantify immune effector-cell activity. We documented that the interaction between cancer cells, their stroma, anticancer agents and cells from the innate system are critical for determining the response of tumors to immunomodulatory strategies.

Entities: CellLine Chemical Disease Gene Species

Year: 2012 PMID： 23243609 PMCID： PMC3518518 DOI： 10.4161/onci.21058

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

10 in total

1. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Authors: Douglas W McMillin; Jake Delmore; Joseph M Negri; Matthew Vanneman; Shohei Koyama; Robert L Schlossman; Nikhil C Munshi; Jacob Laubach; Paul G Richardson; Glenn Dranoff; Kenneth C Anderson; Constantine S Mitsiades
Journal: Blood Date: 2012-01-30 Impact factor: 22.113

Review 2. Immunomodulatory drugs as a therapy for multiple myeloma.

Authors: H De Raeve; K Vanderkerken
Journal: Curr Pharm Biotechnol Date: 2006-12 Impact factor: 2.837

Review 3. Current therapeutic uses of lenalidomide in multiple myeloma.

Authors: Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal: Expert Opin Investig Drugs Date: 2006-02 Impact factor: 6.206

4. The dilemma of anticancer therapy: tumor-specific versus immune effects.

Authors: Laurence Zitvogel; Guido Kroemer
Journal: Blood Date: 2008-12-01 Impact factor: 22.113

Review 5. Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors: Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal: Nat Rev Clin Oncol Date: 2011-03 Impact factor: 66.675

Review 6. Immune microenvironments in solid tumors: new targets for therapy.

Authors: Stephen L Shiao; A Preethi Ganesan; Hope S Rugo; Lisa M Coussens
Journal: Genes Dev Date: 2011-12-15 Impact factor: 11.361

Review 7. Lenalidomide in multiple myeloma.

Authors: Paul G Richardson; Constantine Mitsiades; Teru Hideshima; Kenneth C Anderson
Journal: Expert Rev Anticancer Ther Date: 2006-08 Impact factor: 4.512

8. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.

Authors: Laurence Zitvogel; Guido Kroemer
Journal: J Clin Invest Date: 2009-07-20 Impact factor: 14.808

Review 9. The anticancer immune response: indispensable for therapeutic success?

Authors: Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal: J Clin Invest Date: 2008-06 Impact factor: 14.808

10. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authors: Douglas W McMillin; Jake Delmore; Ellen Weisberg; Joseph M Negri; D Corey Geer; Steffen Klippel; Nicholas Mitsiades; Robert L Schlossman; Nikhil C Munshi; Andrew L Kung; James D Griffin; Paul G Richardson; Kenneth C Anderson; Constantine S Mitsiades
Journal: Nat Med Date: 2010-03-14 Impact factor: 53.440